Andrew J. Schwab
CIK: 0001598549
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (42 total)
- Sep 23, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect4.5K shares at avg. $1.61$7K - Sep 23, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect114.9K shares at avg. $1.61$185K - Sep 22, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect27.6K shares at avg. $1.65$46K - Sep 22, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect1.1K shares at avg. $1.65$2K - Sep 16, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect32.6K shares at avg. $1.91$62K - Sep 16, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect1.3K shares at avg. $1.91$2K - Aug 27, 2026CAMP
Camp4 Therapeutics Corp
Sale(S)Indirect400K shares at avg. $4.04$1.6M - Aug 24, 2026CAMP
Camp4 Therapeutics Corp
Sale(S)Indirect10 shares at avg. $4.50$45 - Aug 21, 2026CAMP
Camp4 Therapeutics Corp
Sale(S)Indirect32K shares at avg. $4.50$144K - Aug 20, 2026CAMP
Camp4 Therapeutics Corp
Sale(S)Indirect114.7K shares at avg. $4.54$521K - Aug 20, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect46 shares at avg. $0.32$14.72 - Aug 20, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect6.5K shares at avg. $0.32$2K - Aug 20, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect1.2K shares at avg. $0.32$370.88 - Aug 19, 2026CAMP
Camp4 Therapeutics Corp
Sale(S)Indirect45.1K shares at avg. $4.76$215K - Aug 19, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect409 shares at avg. $0.35$143.15 - Aug 19, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect10.3K shares at avg. $0.35$4K - Aug 19, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect57.5K shares at avg. $0.35$20K - Aug 18, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect1.8K shares at avg. $0.38$695.4 - Aug 18, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect45.1K shares at avg. $0.38$17K - Aug 18, 2026SKYE
Skye Bioscience, Inc.
Sale(S)Indirect253.1K shares at avg. $0.38$96K - Aug 3, 2026CAMP
Camp4 Therapeutics Corp
Award(A)IndirectPre-Funded Warrant (Right to Buy)
3.2M shares at avg. $1.53- - Jun 10, 2026CAMP
Camp4 Therapeutics Corp
Award(A)DirectStock Option (Right to Buy)
28K shares- - Mar 31, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
75K shares- - Feb 6, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
35K shares- - Sep 11, 2025CAMP
Camp4 Therapeutics Corp
Award(A)Indirect2.9M shares at avg. $1.53$4.5M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 23, 2026 |  SKYE Skye Bioscience, Inc. | Sale(S) | 4,528 | $1.61 | $7,290 | Indirect |
| Sep 23, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 114,851 | $1.61 | $184,910 | Indirect |
| Sep 22, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 27,612 | $1.65 | $45,560 | Indirect |
| Sep 22, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 1,088 | $1.65 | $1,795 | Indirect |
| Sep 16, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 32,607 | $1.91 | $62,279 | Indirect |
| Sep 16, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 1,285 | $1.91 | $2,454 | Indirect |
| Aug 27, 2026 |  CAMP Camp4 Therapeutics Corp | Sale(S) | 400,000 | $4.04 | $1,616,000 | Indirect |
| Aug 24, 2026 | CAMP Camp4 Therapeutics Corp | Sale(S) | 10 | $4.50 | $45 | Indirect |
| Aug 21, 2026 | CAMP Camp4 Therapeutics Corp | Sale(S) | 32,018 | $4.50 | $144,081 | Indirect |
| Aug 20, 2026 | CAMP Camp4 Therapeutics Corp | Sale(S) | 114,700 | $4.54 | $520,738 | Indirect |
| Aug 20, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 46 | $0.32 | $15 | Indirect |
| Aug 20, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 6,495 | $0.32 | $2,078 | Indirect |
| Aug 20, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 1,159 | $0.32 | $371 | Indirect |
| Aug 19, 2026 | CAMP Camp4 Therapeutics Corp | Sale(S) | 45,147 | $4.76 | $214,900 | Indirect |
| Aug 19, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 409 | $0.35 | $143 | Indirect |
| Aug 19, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 10,255 | $0.35 | $3,589 | Indirect |
| Aug 19, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 57,476 | $0.35 | $20,117 | Indirect |
| Aug 18, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 1,830 | $0.38 | $695 | Indirect |
| Aug 18, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 45,090 | $0.38 | $17,134 | Indirect |
| Aug 18, 2026 | SKYE Skye Bioscience, Inc. | Sale(S) | 253,080 | $0.38 | $96,170 | Indirect |
| Aug 3, 2026 | CAMP Camp4 Therapeutics Corp | Award(A) Pre-Funded Warrant (Right to Buy) | 3,179,558 | $1.53 | - | Indirect |
| Jun 10, 2026 | CAMP Camp4 Therapeutics Corp | Award(A) Stock Option (Right to Buy) | 28,000 | - | - | Direct |
| Mar 31, 2026 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 75,000 | - | - | Direct |
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 35,000 | - | - | Direct |
| Sep 11, 2025 | CAMP Camp4 Therapeutics Corp | Award(A) | 2,941,176 | $1.53 | $4,499,999 | Indirect |
1-25 of 42 transactions
About Schwab Andrew J.
Schwab Andrew J. (SEC CIK 0001598549) files insider reports with the SEC as Director of Skye Bioscience, Inc. (SKYE) and Director of Camp4 Therapeutics Corp (CAMP).
Signal8 holds 18 ownership filings by Schwab Andrew J. (1 Form 3, 17 Form 4), filed between Sep 13, 2024 and Sep 24, 2026. Those filings report 42 transactions, from Sep 11, 2024 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schwab Andrew J.'s filings is in SAN FRANCISCO, CA.
Recent filings by Schwab Andrew J.
- Sep 23, 2026: Open-market sales of SKYE shares (2 lines, Form 4, code S).
- Sep 22, 2026: Open-market sales of SKYE shares (2 lines, Form 4, code S).
- Sep 16, 2026: Open-market sales of SKYE shares (2 lines, Form 4, code S).
- Aug 27, 2026: Open-market sale of CAMP shares (Form 4, code S).
- Aug 24, 2026: Open-market sale of CAMP shares (Form 4, code S).
Other insiders filing for Skye Bioscience, Inc. (SKYE)
- 5AM Partners VII, LLC, 10% Owner
- DHILLON PUNIT, Chief Executive Officer
- Sharp John P, Chief Financial Officer
- Smith Karen L., Director
- Twitty Christopher, Chief Scientific Officer
- Jenkins Annalisa, Director